Prof. Dr. Edwin Bremer is a tenure track Professor at the UMCG where he is chair of the section Immunohematology. He was an honorary Associate Professor at Exeter University Medical School (2014-2017) and is Visiting Professor in Harbin (China, 2011-current) and Edmonton (Canada, 2013). His research interests include tumor immunology and immunotherapy, in particular antibody-engineering and antibody-based immunocytokines. He has >45 peer-reviewed articles in the field.
Dr. Valerie Wiersma is a post-doctoral fellow and junior PI focused on the TIM3/Galectin-9 checkpoint in cancer therapy. She has 16 publications in the field and was recently awarded with a prestigious Dutch Cancer Society Young Investigator Award.
Dr. Marco de Bruyn is a staff member of Gynecological Oncology focused on tumor immunological principles as well as (pre)clinical and translational development of novel therapeutics with 29 peer-reviewed publications.
Harald Wajant is Professor at the Department of Internal Medicine II of the University Hospital Würzburg and head the Division of Molecular Internal Medicine. He graduated in the Institute of Botany of the University of Stuttgart, Germany in 1993 and was then a postdoctoral research fellow and group leader at the Institute of Cell Biology and Immunology. Since 2003 he is Professor at the University Hospital Würzburg. In the 1990s during his time in Stuttgart, Professor Wajant worked on the cloning, expression and biotechnological application of plant hydroxynitrile lyases but also started to work in the completely different field of TNF receptor signaling. Since then the scientific interests of Professor Wajant fully shifted to the TNF field and are now focused on the mechanisms of TNF receptor activation, apoptotic and non-apoptotic death receptor signaling and the development of antibodies and TNF ligand fusion proteins targeting TNF receptors. "
PhD, Group leader, Specialist in TNF receptor superfamily signaling research with over 15 experience in academia, Dr. Siegmund received her Ph.D. for work on TNF receptor superfamily (TNFRSF) signaling from the University of Stuttgart and worked afterwards as Posdoc at the University of Heidelberg at the Institute of Molecular Cardiology. Since 2003 she is group leader at the division of Medical Internal Medicine at UKW with a research focus again on TNFRSF signaling.
PhD, Postdoc, Dr. Medler received her Ph.D. in Biology from the Graduate School of life Sciences of the University of Würzburg , Germany. She is working on development on bifunctional anti-TNFRSF receptor fusion proteins for activation of regulatory T cells (Tregs) and treatment of graft versus host disease.
Expert in development of drug delivery systems based on electrospinning and electrospraying. Matej Buzgo studied cell biology at Charles University in Prague. His research career was performed at the Instutute of Experimental Medicine in Prague, Czech Technical University and Charles University. He has participated as team member in the FP7 project BIOSCENT, ERANET project CARSILA and numerous of other Czech projects focused on tissue engineering and nanofiber production. In addition, he has been the main investigator of two grant projects funded by the Grant Agency of Charles University, co-investigator of three H2020 funded projects (DifMATRIX, NanoBAT, transMed). The main reserch experience of Matej Buzgo is in the field of nanomaterials preparation for cell culture, either in the field of tissue engineering or/and laboratory cell culture. He has wide experience in preparation of core/shell nanofibers by needleless electrospinning for drug delivery of proteins and small molecules. In addition, he is an autohor of InoSPIN electrospinning unit and InoMATRIX 3D scaffolds. Matej Buzgo is an author of <20 research publications in renowned journals (H-index 10.0) and holds 8 national patents about scaffold production whereof 1 European patent.
Expert in development of drug delivery systems based on electrospinning and elctrospraying. She has vast experience in preparation and characterization of core/shell nanofibers with embedded liposomes and platelets for delivery of growth factors. She recieved her Ph.D. degree in Medical Biophysics from the Charles University in Prague. Her research career started at the Institute of Experimental Medicine ASCR, v.v.i. and continued at the Czech Technical Univeristy in Prague. She has been a team member of numerous national and international projects. In addition, she was the main investigator of three junior grant projects funded by the Grant Agency of Charles University, co-investigator of MSCA RISE project (iP-OSTEO, NanoFEED) and grants of ministry of heatlhcare (IGA MZ). Andrea is also a co-inventor of several scaffolds for tissue engineering applications protected by national patents and utility models. Her mayor fields of training and research experience are focused on development and characterization of drug delivery systems for biomedical, tissue engineering and veterinary applications (In vitro viand In vo studies). Andrea Staffa is also an author and co-author of more than 15 research publications in renowned journals (H-index 8.0).
Dr. Cagri Üzüm has a background in nanotechnology, polymers and surface science. After his PhD and postdoctoral research at the Technische Universität Berlin, he started working at Surflay Nanotec GmbH, managing client tailored research projects and leading business development.
Dr. habil. Lars Dähne is the founder an CEO Surflay Nanotec GmbH since 2008. He started research on nanocoatings and Layer-by-Layer technology in 1998 at the Max-Planck-Institute of Colloids and Interfaces. In 2001 he co-founded the biotech company Capsulution NanoScience AG. During his career he has published more than 70 peer-reviewed articles in international journals and supervised several bachelors, masters- and PhD students. Dr. Dähne is also a lecturer at the Free University of Berlin.
PhD, VP Research & Development; Research and development senior specialist with over 20 years of industry experience in innovative Biotechnology companies. Prior to joining KAHR, Dr. Chajut served as VP of R&D in multiple companies including Pluristem Therapeutics, Rosetta Genomics and Quark Pharmaceuticals.
Executive leader with over a decade of experience leading worldwide pre-clinical and clinical programs in oncology and immune-oncology. Heading multi-disciplinary teams and managing multi-million-dollar budgets in private and publicly traded companies. Prior to joining KAHR, served as Chief Development Officer at Cellect Biotechnology (APOP) and as Senior Director of Oncology at BioLineRx (BLRX). Prior to that held R&D positions at Genentech, a leading biotechnology company, member of the Roche Group.